We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited s... Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Show more
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS. Robert Plenge, M.D., Ph.D., Executive Vice President...
Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or...
Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its...
Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and address inquiries from...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company...
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors, demonstrating clinically meaningful response...
Late-breaking data to be presented at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.75 | 1.88679245283 | 39.75 | 41.66 | 39.35 | 13977757 | 40.48154087 | CS |
4 | -0.88 | -2.12663122281 | 41.38 | 43.04 | 39.35 | 17237947 | 41.22524506 | CS |
12 | -7.71 | -15.9925326696 | 48.21 | 49.56 | 39.35 | 15501969 | 42.65099875 | CS |
26 | -9.89 | -19.6269101012 | 50.39 | 55.035 | 39.35 | 15602344 | 47.11488728 | CS |
52 | -22.38 | -35.5916030534 | 62.88 | 65.375 | 39.35 | 14252861 | 50.96247301 | CS |
156 | -26.63 | -39.6692983763 | 67.13 | 81.435 | 39.35 | 11918513 | 61.74698007 | CS |
260 | -4.05 | -9.09090909091 | 44.55 | 81.435 | 39.35 | 12380512 | 60.64674573 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions